You are here: Industry Insights > cancer

News List

China Pharmaceutical Industry Rankings Released: The Top 10 Unchanged Muzi
August 17, 2018
The list of top 100 pharmaceutical industry enterprises of previous year would be released in the China Pharmaceutical Industry Information Annual Conference hosted by China National Pharmaceutical Industry Center, and this year is no exception.
PHE data shows link between cancer diagnosis route and treatment pharmatimes
August 17, 2018
Public Health England (PHE) has revealed new data showing that the way that cancer patients are diagnosed can affect their treatment options.
Most Postmenopausal Bleeding Not Associated With Cancer drugs
August 15, 2018
Most women with postmenopausal bleeding (PMB) will not be diagnosed with endometrial cancer, according to a review published online Aug. 6 in JAMA Internal Medicine.
Jury Awards $289 Million in Case Linking Roundup to Man's Cancer drugs
August 14, 2018
A $289 million award against Monsanto in a case linking its Roundup week killer to terminal cancer in a former school groundskeeper may lead to similar judgments against the company, according to the man's lawyers.
Researchers develop AI technique to treat cancer biospectrumasia
August 14, 2018
The new "self-learning" machine-learning technique could make the dosing regimen less toxic but still effective
Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD Join Lixte Biotechnology’s Board of Directors biospectrumasia
August 13, 2018
Dr. Yen also founded philanthropic organizations aimed at serving the global cancer community and holds membership in numerous professional societies. He serves on the boards of Fulgent Genetics and Tanvex BioPharma Inc.
Pfizer drops diabetes and cancer drugs from clinical pipeline fiercebiotech
August 01, 2018
Pfizer has culled Type 1 diabetes and cancer drugs from its early-phase pipeline (PDF). The actions affect anti-IL7R antibody PF-06342674 and third-generation, mutant-selective EGFR tyrosine kinase inhibitor PF-06747775.
JCVI backs HPV jab for boys pharmatimes
July 25, 2018
The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
BI snaps up OSE’s novel checkpoint inhibitor pharmatimes
July 18, 2018
Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours.
NICE approves treatment for rare and deadly childhood cancer pharmafile
July 17, 2018
NICE has recommended that monoclonal antibody dinutuximab beta be used in treating high-risk neuroblastoma – a rare and deadly form of cancer that mainly affects young children.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page